MedTrace Logo

Magnesium and Vitamin D Combination for Post-COVID Syndrome

NCT05630339 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-09-28

No results posted yet for this study

Summary

The goal of this double-blind randomized controlled clinical trial is to determine the efficacy of the administration of magnesium chloride + vitamin D as an adjuvant in the treatment of post-Coronavirus Disease (COVID) syndrome.

The participants will be integrated: a) Intervention group that will receive 1 g of magnesium chloride (equivalent to 300 mg of elemental magnesium) + 4000 IU of vitamin D once a day, for four months. b) Control group that will receive inert placebo for four months.

The outcome variable will be the improvement of the post-COVID syndrome. At the beginning and end of the study, blood samples will be taken to determine serum levels of vitamin D, total magnesium, ionic magnesium, calcium, fasting glucose and lipid profile.

The evaluation of the efficacy and safety of the proposed intervention will be carried out by establishing the differences between the intervention and control groups.

Conditions

  • Post-COVID-19 Syndrome
  • Long COVID
  • Vitamin D Deficiency
  • Magnesium Deficiency

Interventions

DIETARY_SUPPLEMENT

Magnesium chloride

Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.

DIETARY_SUPPLEMENT

Vitamin D

Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.

DIETARY_SUPPLEMENT

Inert placebo

Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.

Sponsors & Collaborators

  • Consejo de Ciencia y Tecnología del Estado de Durango

    collaborator UNKNOWN

  • Coordinación de Investigación en Salud, Mexico

    lead OTHER_GOV

Principal Investigators

  • Fernando Guerrero, PhD · Instituto Mexicano del Seguro Social

  • Gerardo Martínez, PhD · Instituto Mexicano del Seguro Social

  • Luis Simental, PhD · Instituto Mexicano del Seguro Social

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-30
Primary Completion
2023-05-01
Completion
2023-09-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630339 on ClinicalTrials.gov